((自动化翻译由路透提供，请见免责声明 ))
1月7日 - ** 英纳利医疗 股价盘前上涨约21%，至78.50美元。
** 较大的竞争对手史赛克公司 周一晚些时候同意以49亿美元的全现金交易收购 (link) NARI。
** NARI公司生产治疗静脉疾病的器械，这项交易有助于史赛克扩大其治疗静脉血栓栓塞症（一种静脉内形成血栓的疾病）和其他血管疾病的产品范围。
** 作为交易的一部分，史赛克将以每股 80 美元的价格收购 Inari，路透最早报导了这一交易 (link)。
** 截至上次收盘，NARI 的股价在过去 12 个月中上涨了 ~2
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.